ValuEngine upgraded shares of Bellerophon Therapeutics (NASDAQ:BLPH) from a sell rating to a hold rating in a report released on Tuesday.
Several other research firms have also recently commented on BLPH. Zacks Investment Research raised Bellerophon Therapeutics from a hold rating to a buy rating and set a $2.25 price objective on the stock in a research report on Thursday, March 22nd. HC Wainwright reaffirmed a buy rating on shares of Bellerophon Therapeutics in a research report on Tuesday, March 20th.
Shares of Bellerophon Therapeutics stock traded up $0.03 during trading on Tuesday, hitting $2.00. 23,395 shares of the company’s stock traded hands, compared to its average volume of 192,061. Bellerophon Therapeutics has a 1 year low of $1.00 and a 1 year high of $2.74. The stock has a market capitalization of $113.59, a PE ratio of -2.19 and a beta of -0.39.
Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in shares of Bellerophon Therapeutics during the fourth quarter valued at $146,000. Bank of New York Mellon Corp purchased a new stake in shares of Bellerophon Therapeutics during the fourth quarter valued at $458,000. EAM Investors LLC purchased a new stake in shares of Bellerophon Therapeutics during the fourth quarter valued at $614,000. Vanguard Group Inc. boosted its position in shares of Bellerophon Therapeutics by 52.6% during the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after buying an additional 211,111 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Bellerophon Therapeutics by 25.3% during the fourth quarter. Renaissance Technologies LLC now owns 927,200 shares of the biotechnology company’s stock valued at $2,392,000 after buying an additional 187,200 shares during the last quarter. 57.57% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3335455/bellerophon-therapeutics-blph-raised-to-hold-at-valuengine.html.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.